# Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT04480307** · PHASE2 · COMPLETED · sponsor: **GeNeuro Innovation SAS** · enrollment: 41 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** temelimab 18 mg/kg
- **DRUG:** temelimab 36 mg/kg
- **DRUG:** temelimab 54 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04480307
- **Lead sponsor:** GeNeuro Innovation SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-01-24
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480307, "Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04480307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*